首页 | 本学科首页   官方微博 | 高级检索  
检索        

NP与EP方案治疗晚期非小细胞肺癌的观察
引用本文:杜煦.NP与EP方案治疗晚期非小细胞肺癌的观察[J].医学综述,2013(19):3606-3608.
作者姓名:杜煦
作者单位:重庆市九龙坡区第二人民医院呼吸内科,重庆400052
摘    要:目的 观察并比较去甲长春花碱(NVB)联合顺铂(NP方案)与足叶乙苷(VP-16)联合顺铂(EP方案)两种化疗方案对晚期非小细胞肺癌(NSCLC)的治疗效果.方法 收集2009年11月2011 年11月由重庆市九龙坡区第二人民医院呼吸内科收治的晚期NSCLC患者68例,随机分为NP组38例和EP组30例,给予3个周期的治疗后评估其疗效和不良反应.结果 NP组中获得完全缓解和部分缓解的例数显著高于EP组,两组的近期疗效比较差异有统计学意义(u=3.5961,P〈0.05).两组患者均发生不同程度的胃肠反应、骨髓抑制和静脉炎不良反应,但比较差异无统计学意义(u=1.3669,0.7983,1.1674,P〉0.05).结论 NP方案价格较低、耐受性较好,是治疗NSCLC疗效较好的方案之一.

关 键 词:非小细胞肺癌  去甲长春花碱  足叶乙甙  顺铂  化疗

Observation of NP and EP Regimen in Treatment of Advanced Non-small Cell Lung Cancer
Institution:DU Xi. ( Department of Respiratory, the Second People's Hospital in Jiulongpo District, Chongqing 400052, China )
Abstract:Objective To observe and compare the clinical effect of NP regimen( navelbine combined with cisplatin)and EP regimen (etoposide combined with cisplatin)in treating with the advanced non-small cell lung cancer ( NSCLC ). Methods From November 2009 to November 2011,68 cases of advanced NSCLC from Department of Respiratory,the Second People's Hospital in Jiutongt)o District were collected and divided into NP regimen group(38 cases)and EP regimen group(30 cases)randomly. The clinical effect and ad,erse reaction were eva|uaed after 3 circles of therapy. Results The complete remission(CR) and partial remission(PR) cases of NP regimen were significantly more than the EP regimen, the difference in short- period therapeutic effect was statistically significant( u = 3. 5961 ,P 〈 O. 05 ). Adverse reaction such as gastro- intestinal reaction, bone marrow depression and phlebitis occurred in all cases of each group, but there was no significant difference between them ( a = 1. 3669,0. 7983,1.16"/4, P 〉 0.05 ). Conclusion NP regimen, which is well tolerated and has lower prices ,is one of the good programs for the treatment of NSCLC.
Keywords:Non-small cell lung cancer  Navelbine  Etoposide  Cisplatin  Chemotherapy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号